Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the sale, the executive vice president now directly owns 118,469 shares of the company's stock, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Rong Zhou also recently made the following trade(s):
- On Tuesday, November 12th, Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84.
Amphastar Pharmaceuticals Price Performance
Shares of AMPH stock traded down $1.40 on Monday, reaching $40.84. The company's stock had a trading volume of 597,259 shares, compared to its average volume of 402,867. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The stock's 50 day simple moving average is $47.14 and its 200-day simple moving average is $44.65. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.96 billion, a P/E ratio of 13.61, a PEG ratio of 0.87 and a beta of 0.78.
Institutional Trading of Amphastar Pharmaceuticals
A number of large investors have recently modified their holdings of AMPH. GAMMA Investing LLC increased its position in shares of Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after purchasing an additional 273 shares during the last quarter. Innealta Capital LLC bought a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth $55,000. Point72 Asia Singapore Pte. Ltd. boosted its stake in Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after buying an additional 398 shares in the last quarter. Blue Trust Inc. raised its position in Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. purchased a new position in shares of Amphastar Pharmaceuticals in the third quarter worth about $78,000. Institutional investors own 65.09% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on AMPH. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price objective on the stock. StockNews.com lowered Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $60.33.
View Our Latest Report on AMPH
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
